Special Issue

Medical Cannabis and Its Derivatives

Message from the Guest Editors

This Special Issue aims to provide a comprehensive overview of the latest research developments in medical cannabis and its derivatives. It will explore the various medical applications of cannabis and its compounds, including CBD, THC, and other cannabinoids. It will also examine the potential risks and benefits associated with medical cannabis use, as well as the legal and regulatory challenges surrounding its use. The Special Issue will cover a range of topics related to medical cannabis and its derivatives, including, but not limited to, the following:

- The pre-clinical and clinical pharmacology and therapeutic potential of cannabinoids in different medical conditions;
- The role of the endocannabinoid system in health and disease and how cannabis-derived compounds can interact with this system;
- The development and testing of cannabis-based pharmaceuticals, including clinical trials and regulatory issues;
- The use of medical cannabis in specific population groups, such as pediatric patients, including the potential risks and benefits;
- Delivery systems of cannabis extracts and/or their components, including studies employing traditional and modern alternatives.

Guest Editors

Dr. Priscila Mazzola

Faculty of Pharmaceutical Sciences, University of Campinas (UNICAMP), Campinas 13083-871, Brazil

Prof. Dr. José Luiz Costa

Faculty of Pharmaceutical Sciences, University of Campinas (UNICAMP), Campinas 13083-871, Brazil

Deadline for manuscript submissions

closed (25 February 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/169517

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

